New Zealand markets open in 8 hours 5 minutes

Acorda Therapeutics, Inc. (CDG.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
8.420.00 (0.00%)
As of 03:32PM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 17.53M
Enterprise value 160.15M
Trailing P/E 0.97
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.10
Price/book (mrq)0.17
Enterprise value/revenue 1.44
Enterprise value/EBITDA 3.63

Trading information

Stock price history

Beta (5Y monthly) 1.73
52-week change 3-50.16%
S&P500 52-week change 323.49%
52-week high 318.40
52-week low 37.64
50-day moving average 38.42
200-day moving average 38.75

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 51.24M
Implied shares outstanding 61.67M
Float 81.23M
% held by insiders 10.64%
% held by institutions 113.93%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 305 Jun 2023

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -227.75%
Operating margin (ttm)-65.98%

Management effectiveness

Return on assets (ttm)-6.59%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)115.66M
Revenue per share (ttm)93.13
Quarterly revenue growth (yoy)-8.80%
Gross profit (ttm)N/A
EBITDA 551k
Net income avi to common (ttm)-263.42M
Diluted EPS (ttm)8.70
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.36M
Total cash per share (mrq)7.54
Total debt (mrq)195.92M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.22
Book value per share (mrq)-149.56

Cash flow statement

Operating cash flow (ttm)-27.15M
Levered free cash flow (ttm)6.01M